Sanofi Seeks Independence For API Unit Despite Stormy Market
IPO Plans Shelved In Favor Of Spin-Off
Executive Summary
The French drugmaker is pushing ahead with a listing of its Euroapi business on the Euronext in the next couple of months, in spite of the turbulence that the Russian invasion of Ukraine has brought to stock markets.
You may also be interested in...
Sanofi Takes Manufacturing Up A Gear With McLaren Pact
By tapping into the data analytics and expertise used to choreograph pitstops in Formula One, the French drugmaker is hoping to “maximize performance and operational excellence,” according to CEO Paul Hudson.
Sanofi Unruffled By JAK Threat To Dupixent
CEO Paul Hudson tells Scrip that in an atopic dermatitis market that has a standard of care like Dupixent, "it's hard to justify the role of a JAK unless somebody has, frankly, failed everything else."
Sanofi's Rilzabrutinib Fails At First Hurdle In Pemphigus Study
Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.